300181 佐力药业
已收盘 09-14 15:00:00
资讯
新帖
简况
股市必读:佐力药业新发布《国金证券股份有限公司关于浙江佐力药业股份有限公司向不特定对象发行可转换公司债券之发行保荐书(2026年半年度财务数据更新版)》
证券之星 · 09-11
股市必读:佐力药业新发布《国金证券股份有限公司关于浙江佐力药业股份有限公司向不特定对象发行可转换公司债券之发行保荐书(2026年半年度财务数据更新版)》
佐力药业(300181)披露药品生产许可证变更公告,9月1日股价上涨0.81%
证券之星 · 09-01
佐力药业(300181)披露药品生产许可证变更公告,9月1日股价上涨0.81%
开源证券:给予佐力药业买入评级
证券之星 · 09-01
开源证券:给予佐力药业买入评级
佐力药业(300181)6月30日股东户数4.42万户,较上期增加6.37%
证券之星 · 08-28
佐力药业(300181)6月30日股东户数4.42万户,较上期增加6.37%
佐力药业(300181.SZ)发布上半年业绩,归母净利润3.75亿元,同比增长0.38%
智通财经 · 08-27
佐力药业(300181.SZ)发布上半年业绩,归母净利润3.75亿元,同比增长0.38%
图解佐力药业中报:第二季度单季净利润同比下降8.84%
证券之星 · 08-27
图解佐力药业中报:第二季度单季净利润同比下降8.84%
佐力药业2026年半年报:新资产并表助增收,利润增速平缓
蓝鲸财经 · 08-27
佐力药业2026年半年报:新资产并表助增收,利润增速平缓
深交所创业板再融资动态数据周报(2026.08.17-2026.08.23)
中金财经 · 08-25
深交所创业板再融资动态数据周报(2026.08.17-2026.08.23)
佐力药业(300181.SZ):灵莲花颗粒获得药物临床试验批准
智通财经 · 08-12
佐力药业(300181.SZ):灵莲花颗粒获得药物临床试验批准
股市必读:佐力药业新发布《关于2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市的公告》
证券之星 · 08-07
股市必读:佐力药业新发布《关于2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市的公告》
佐力药业(300181)披露2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市公告,8月5日股价下跌1.54%
证券之星 · 08-05
佐力药业(300181)披露2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市公告,8月5日股价下跌1.54%
佐力药业(300181)披露向不特定对象发行可转换公司债券募集说明书(上会稿),7月20日股价上涨6.49%
证券之星 · 07-20
佐力药业(300181)披露向不特定对象发行可转换公司债券募集说明书(上会稿),7月20日股价上涨6.49%
7月20日佐力药业涨6.49%,宏利效率混合LOF基金重仓该股
证券之星 · 07-20
7月20日佐力药业涨6.49%,宏利效率混合LOF基金重仓该股
佐力药业涨6.49%,东吴证券二个月前给出“买入”评级
证券之星 · 07-20
佐力药业涨6.49%,东吴证券二个月前给出“买入”评级
7月17日佐力药业跌5.90%,宏利效率混合LOF基金重仓该股
证券之星 · 07-17
7月17日佐力药业跌5.90%,宏利效率混合LOF基金重仓该股
7月14日佐力药业涨5.24%,宏利效率混合LOF基金重仓该股
证券之星 · 07-14
7月14日佐力药业涨5.24%,宏利效率混合LOF基金重仓该股
佐力药业涨5.24%,东吴证券二个月前给出“买入”评级
证券之星 · 07-14
佐力药业涨5.24%,东吴证券二个月前给出“买入”评级
佐力药业:公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份
证券之星 · 07-09
佐力药业:公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份
佐力药业:目前除了灵泽片外,还有灵莲花颗粒
证券之星 · 07-09
佐力药业:目前除了灵泽片外,还有灵莲花颗粒
佐力药业:公司向不特定对象发行可转换公司债券已获深圳证券交易所受理
证券之星 · 07-09
佐力药业:公司向不特定对象发行可转换公司债券已获深圳证券交易所受理
加载更多
公司概况
公司名称:
浙江佐力药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-02-22
主营业务:
浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵胶囊、灵泽片、灵莲花颗粒、百令片、百令胶囊、聚卡波非钙片/颗粒。公司荣获“全国文明单位”“国家级绿色工厂”“浙江省知名商号”“浙江省重合同、守信用AAA级企业”“浙江省信用管理示范企业”“浙江省中医药文化宣传教育基地”等称号和荣誉。
发行价格:
23.50
{"stockData":{"symbol":"300181","market":"SZ","secType":"STK","nameCN":"佐力药业","latestPrice":13.31,"timestamp":1789369395000,"preClose":13.17,"halted":0,"volume":5940558,"delay":0,"changeRate":0.0106,"floatShares":602000000,"shares":701000000,"eps":0.9031,"marketStatus":"已收盘","change":0.14,"latestTime":"09-14 15:00:00","open":13.16,"high":13.33,"low":13.12,"amount":78711600,"amplitude":0.0159,"askPrice":13.31,"askSize":453,"bidPrice":13.3,"bidSize":93,"shortable":0,"etf":0,"ttmEps":0.9031,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"adjPreClose":13.17,"symbolType":"stock","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":14.49,"lowLimit":11.85,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":701387335,"isCdr":false,"pbRate":2.78,"roa":"--","peRate":14.738124,"roe":"11.25%","epsLYR":0.92,"committee":0.022364,"marketValue":9335000000,"turnoverRate":0.0099,"status":0,"floatMarketCap":8019000000},"requestUrl":"/m/hq/s/300181/","defaultTab":"news","newsList":[{"id":"2666590395","title":"股市必读:佐力药业新发布《国金证券股份有限公司关于浙江佐力药业股份有限公司向不特定对象发行可转换公司债券之发行保荐书(2026年半年度财务数据更新版)》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666590395?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:41","pubTimestamp":1789062069,"startTime":"0","endTime":"0","summary":"公司公告汇总:佐力药业向不特定对象发行可转债申请已于2026年8月21日获深交所上市审核委员会审议通过,募集说明书等文件已基于2026年半年报完成财务数据更新。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600109","300181","BK0028","BK0077","BK0188","BK0201","BK0042","BK0276","BK0183","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664403852","title":"佐力药业(300181)披露药品生产许可证变更公告,9月1日股价上涨0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664403852","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664403852?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:18","pubTimestamp":1788272336,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘,佐力药业报收于13.76元,较前一交易日上涨0.81%,最新总市值为96.51亿元。该股当日开盘13.69元,最高13.77元,最低13.61元,成交额达1.59亿元,换手率为1.93%。近日,浙江佐力药业股份有限公司完成《药品生产许可证》变更,取得浙江省药品监督管理局换发的证书。相关变更已在许可证正本、副本及变更页中载明。此次变更有利于公司拓展产品管线、优化资源配置,短期内对公司业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100042840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","300181","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855645","title":"开源证券:给予佐力药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855645","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664855645?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:20","pubTimestamp":1788261642,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,巢舒然近期对佐力药业进行研究并发布了研究报告《公司信息更新报告:2026H1业绩稳健增长,构建“乌灵+X”生态体系》,给予佐力药业买入评级。 佐力药业 经营业绩稳健增长,维持“买入”评级 公司2026H1实现营收17.64亿元;归母净利润3.75亿元;扣非归母净利润3.74亿元。最新盈利预测明细如下:该股最近90天内共有1家机构给出评级,买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100036460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662291066","title":"佐力药业(300181)6月30日股东户数4.42万户,较上期增加6.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662291066","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662291066?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:51","pubTimestamp":1787910716,"startTime":"0","endTime":"0","summary":"证券之星消息,近日佐力药业披露,截至2026年6月30日公司股东户数为4.42万户,较3月31日增加2646.0户,增幅为6.37%。在中药行业个股中,佐力药业股东户数低于行业平均水平,截至6月30日,中药行业平均股东户数为5.16万户。从股价来看,2026年3月31日至2026年6月30日,佐力药业区间跌幅为7.51%,在此期间股东户数增加2646.0户,增幅为6.37%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0042","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662169089","title":"佐力药业(300181.SZ)发布上半年业绩,归母净利润3.75亿元,同比增长0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662169089","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662169089?lang=zh_cn&edition=full","pubTime":"2026-08-27 23:14","pubTimestamp":1787843656,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佐力药业(300181.SZ)发布2026年半年度报告,报告期内,公司实现营业收入17.64亿元,同比增长10.30%。实现归属于上市公司股东的净利润3.75亿元,同比增长0.38%。实现归属于上市公司股东的扣除非经常性损益的净利润3.74亿元,同比增长0.53%。乌灵系列营业收入较上年同期减少了0.82%,百令系列营业收入较上年同期增长了12.87%,中药饮片营业收入较上年同期数减少了13.82%,中药配方颗粒营业收入较上年同期增长了31.29%,多微系列新增营业收入10,047.36万元,佐力医药公司商业营业收入较上年同期数增长了49.97%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662701858","title":"图解佐力药业中报:第二季度单季净利润同比下降8.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662701858","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662701858?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:11","pubTimestamp":1787829076,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业2026年中报显示,上半年度公司主营收入17.64亿元,同比上升10.3%;归母净利润3.75亿元,同比上升0.38%;扣非净利润3.74亿元,同比上升0.53%;其中2026年第二季度,公司单季度主营收入8.66亿元,同比上升11.78%;单季度归母净利润1.75亿元,同比下降8.84%;单季度扣非净利润1.75亿元,同比下降8.16%;负债率34.89%,投资收益-126.16万元,财务费用748.9万元,毛利率62.62%。财报数据概要请见下图:本文数据来源于佐力药业2026年中报,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700045315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703467","title":"佐力药业2026年半年报:新资产并表助增收,利润增速平缓","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703467","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662703467?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:38","pubTimestamp":1787823539,"startTime":"0","endTime":"0","summary":"财报数据显示,报告期公司实现营业收入17.64亿元,同比增长10.30%;归母净利润3.75亿元,同比增长0.38%;扣非净利润3.74亿元,同比增长0.53%。经营活动产生的现金流量净额为2.30亿元,同比下降20.53%,主要系职工薪酬及税费支付增加所致。值得注意的是,公司于2025年底收购的多种微量元素注射液资产组在本期贡献营收1.00亿元,毛利率超90%,显著增厚了业绩。医药流通板块营收3.73亿元,同比增长9.24%,但毛利率仅为7.07%,对整体利润贡献有限。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787821408479835594","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["300181","BK0042","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662789590","title":"深交所创业板再融资动态数据周报(2026.08.17-2026.08.23)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662789590","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662789590?lang=zh_cn&edition=full","pubTime":"2026-08-25 14:20","pubTimestamp":1787638801,"startTime":"0","endTime":"0","summary":"览富财经网讯:据深交所官网披露,2026 年 8 月 17 日至 8 月 23 日期间,深交所创业板再融资市场保持活跃,共有 12 家企业的再融资项目迎来关键节点,涵盖受理、问询、审核通过、注册生效及终止等多个环节,合计拟募资金额约 126.34 亿元。受理环节方面,本周共有 4 家企业获受理。问询环节方面,恒勃股份、温州宏丰2 家企业收到问询函。此外,商络电子、泰林生物2 家企业可转债项目终止(撤回),分别拟募资 10 亿元、2.3 亿元。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/25/20260825779922.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/25/20260825779922.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260825/32346097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0039","301225","BK0224","BK0061","BK0102","BK0250","300048","BK0146","BK0028","300093","BK0046","BK0251","BK0014","300397","BK0238","300283","BK0077","BK0042","300975","300018","BK0024","BK0264","BK0214","BK0078","301116","BK0005","BK0235","BK0239","BK0130","BK0114","301018","300991","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658785469","title":"佐力药业(300181.SZ):灵莲花颗粒获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2658785469","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658785469?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:51","pubTimestamp":1786524709,"startTime":"0","endTime":"0","summary":"智通财经APP讯,佐力药业 发布公告,公司于近日收到国家药品监督管理局签发的《药物临床试验批准通知书》,同意公司已上市产品灵莲花颗粒开展新增功能主治的临床试验研究。经审查,2026年06月01日受理的灵莲花颗粒临床试验申请符合药品注册的有关要求,在进一步完善临床试验方案的基础上,同意本品开展用于围绝经期综合征伴焦虑状态心肾不交证的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478986.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0077","BK0042","IBBQ","BMED","PSYK","IBBJ","300181","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657659672","title":"股市必读:佐力药业新发布《关于2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657659672","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657659672?lang=zh_cn&edition=full","pubTime":"2026-08-07 01:22","pubTimestamp":1786036934,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘,佐力药业报收于13.99元,下跌0.85%,换手率3.12%,成交量18.84万手,成交额2.63亿元。公司公告汇总:佐力药业完成2024年限制性股票激励计划预留授予部分第一个归属期登记,归属股票30万股,占总股本0.04%,归属价格7.13元/股,公司层面2025年净利润同比增长31.97%。本次归属不设限售期,公司总股本不变,不影响股权结构。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700001601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0077","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657523806","title":"佐力药业(300181)披露2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市公告,8月5日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523806","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657523806?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:20","pubTimestamp":1785939626,"startTime":"0","endTime":"0","summary":"近日,浙江佐力药业股份有限公司发布《关于2024年限制性股票激励计划预留授予部分第一个归属期归属结果暨股份上市的公告》。公告显示,公司于2026年8月5日完成2024年限制性股票激励计划预留授予部分第一个归属期的归属登记,本次归属激励对象共8人,归属股票数量为30万股,占公司总股本的0.04%,股票来源为公司从二级市场回购的A股普通股。本次归属不设限售期,公司总股本不变,不影响股权结构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","300181","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652291239","title":"佐力药业(300181)披露向不特定对象发行可转换公司债券募集说明书(上会稿),7月20日股价上涨6.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652291239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652291239?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:43","pubTimestamp":1784540583,"startTime":"0","endTime":"0","summary":"截至2026年7月20日收盘,佐力药业报收于14.77元,较前一交易日上涨6.49%,最新总市值为103.59亿元。该股当日开盘13.82元,最高14.98元,最低13.75元,成交额达6.05亿元,换手率为6.91%。近日,浙江佐力药业股份有限公司发布《向不特定对象发行可转换公司债券募集说明书(上会稿)》。公告显示,本次发行已获董事会及股东大会审议通过。公司主体及债券信用等级均为AA,评级展望稳定。本次发行未提供担保。报告期内财务报告经审计,均出具标准无保留意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000027344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0239","BK0077","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652299880","title":"7月20日佐力药业涨6.49%,宏利效率混合LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652299880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652299880?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:45","pubTimestamp":1784537121,"startTime":"0","endTime":"0","summary":"证券之星消息,7月20日佐力药业涨6.49%,收盘报14.77元,换手率6.91%,成交量41.67万手,成交额6.05亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为宏利基金的宏利效率混合LOF。周笑雯在任的基金产品包括:宏利医药健康混合发起A,管理时间为2023年12月26日至今,期间收益率为-9.06%;宏利效率混合LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0077","BK0042","162207","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652054296","title":"佐力药业涨6.49%,东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2652054296","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652054296?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:45","pubTimestamp":1784537112,"startTime":"0","endTime":"0","summary":"今日佐力药业(300181)涨6.49%,收盘报14.77元。2026年4月30日,东吴证券研究员朱国广,向潇发布了对佐力药业的研报《2025年报&2026一季报点评,乌灵系列稳健增长,“一路向 C”战略持续深化》,该研报对佐力药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为84.97%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为长城证券的刘鹏。佐力药业(300181)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","300181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652471406","title":"7月17日佐力药业跌5.90%,宏利效率混合LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652471406","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652471406?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:49","pubTimestamp":1784278196,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日佐力药业跌5.90%,收盘报13.87元,换手率6.19%,成交量37.33万手,成交额5.29亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为宏利基金的宏利效率混合LOF。周笑雯在任的基金产品包括:宏利医药健康混合发起A,管理时间为2023年12月26日至今,期间收益率为0.07%;宏利效率混合LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0077","BK0042","BK0239","162207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651175824","title":"7月14日佐力药业涨5.24%,宏利效率混合LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651175824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651175824?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:29","pubTimestamp":1784017788,"startTime":"0","endTime":"0","summary":"证券之星消息,7月14日佐力药业涨5.24%,收盘报14.87元,换手率7.11%,成交量42.89万手,成交额6.27亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共1家,其中持有数量最多的公募基金为宏利基金的宏利效率混合LOF。周笑雯在任的基金产品包括:宏利医药健康混合发起A,管理时间为2023年12月26日至今,期间收益率为-3.73%;宏利效率混合LOF的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400030803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","BK0042","BK0077","BK0239","162207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651175828","title":"佐力药业涨5.24%,东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651175828","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651175828?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:29","pubTimestamp":1784017779,"startTime":"0","endTime":"0","summary":"今日佐力药业(300181)涨5.24%,收盘报14.87元。2026年4月30日,东吴证券研究员朱国广,向潇发布了对佐力药业的研报《2025年报&2026一季报点评,乌灵系列稳健增长,“一路向 C”战略持续深化》,该研报对佐力药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为84.97%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为长城证券的刘鹏。佐力药业(300181)个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400030800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300181","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650874942","title":"佐力药业:公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2650874942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650874942?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:51","pubTimestamp":1783583479,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业07月09日在投资者关系平台上答复投资者关心的问题。这是贵司参股的科济药业,贵司按目前股价已大赚了3亿多?介绍科济药业抗癌?公司通过二级子公司佐力创新医疗持有科济药业28,385,012股股份,属于其他权益工具投资,其公允价值变动计入公司其他综合收益。科济药业具体情况请详见其在港交所发布的相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900025187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1585","BK0239","BK1574","002173","BK0236","BK1587","BK0096","300181","02171","BK0077","BK0042","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650942809","title":"佐力药业:目前除了灵泽片外,还有灵莲花颗粒","url":"https://stock-news.laohu8.com/highlight/detail?id=2650942809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650942809?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:51","pubTimestamp":1783583477,"startTime":"0","endTime":"0","summary":"公司深耕优势领域,聚焦乌灵系列创新中药的研发,目前除了灵泽片外,还有灵莲花颗粒,该品种为国内独家产品、OTC品种;另有多个乌灵系列创新药在研发阶段,其中,灵香片、参灵颗粒处于临床试验阶段,还有其他治疗方向的乌灵系列创新中药正在进行临床前的毒理和药学研究,公司稳步推进“立项一批,临床一批,上市一批”的合理布局,致力于将乌灵系列打造成10个产品的大家庭。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900025179.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0042","300181","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650428799","title":"佐力药业:公司向不特定对象发行可转换公司债券已获深圳证券交易所受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2650428799","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650428799?lang=zh_cn&edition=full","pubTime":"2026-07-09 15:51","pubTimestamp":1783583476,"startTime":"0","endTime":"0","summary":"证券之星消息,佐力药业(300181)07月09日在投资者关系平台上答复投资者关心的问题。投资者提问:公司向不特定对象发行可转换公司债券的进展如何?佐力药业回复:您好!公司向不特定对象发行可转换公司债券已获深圳证券交易所受理,审核程序正在积极推进中,公司将根据进展及时履行信息披露义务。感谢您的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900025178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399001","300181","BK0239","BK0042","BK0077"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789417655813,"stockEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.1091},{"period":"3month","weight":0.0114},{"period":"6month","weight":-0.1657},{"period":"1year","weight":-0.2558},{"period":"ytd","weight":-0.1558}],"compareEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0107},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0038},{"period":"ytd","weight":-0.021}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江佐力药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"44196人(较上一季度增加6.37%)","perCapita":"13632股","listingDate":"2011-02-22","address":"浙江省湖州市德清县阜溪街道志远北路388号","registeredCapital":"70138万元","survey":" 浙江佐力药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是乌灵胶囊、灵泽片、灵莲花颗粒、百令片、百令胶囊、聚卡波非钙片/颗粒。公司荣获“全国文明单位”“国家级绿色工厂”“浙江省知名商号”“浙江省重合同、守信用AAA级企业”“浙江省信用管理示范企业”“浙江省中医药文化宣传教育基地”等称号和荣誉。","listedPrice":23.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佐力药业,300181,佐力药业股票,佐力药业股票老虎,佐力药业股票老虎国际,佐力药业行情,佐力药业股票行情,佐力药业股价,佐力药业股市,佐力药业股票价格,佐力药业股票交易,佐力药业股票购买,佐力药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佐力药业(300181)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佐力药业(300181)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}